Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab + TCS in Cyclosporine-Experienced AD (ADvantage)
NCT05149313Phase 3Completed
- Sponsor
- Almirall
- Start
- Dec 2021
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Lebrikizumab + TCS with Placebo + TCS (2 arms). Primary endpoint: Proportion of Participants Achieving >=75% Reduction in Eczema Area and Severity Index at 16 weeks. Started Dec 2021; status: completed.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05149313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05149313.